Novartis Is Spending $2B to Replace Its Own Blockbuster Drug

But what makes Excellergy interesting isn't the résumés. It's the science.

Xolair Catches the Fish; Exl-111 Takes Back the Whole Pond

To understand why Novartis is so excited, you need a quick primer on how allergy drugs work.

Your immune system produces an antibody called IgE (immunoglobulin E). In people with allergies, IgE goes haywire. It latches onto immune cells called mast cells and basophils, and when an allergen shows up (pollen, peanuts, cat dander), those IgE molecules tell the immune cells to release histamine and other inflammatory chemicals. That's what causes sneezing, hives, swelling, and in severe cases, anaphylaxis.

Xolair works by grabbing free-floating IgE before it can attach to immune cells. Think of it as intercepting a letter before it reaches the mailbox. The problem? It can't do anything about the IgE that's already stuck to immune cells. Those molecules keep triggering reactions.

Excellergy's Exl-111 takes a fundamentally different approach. The company calls it a trifunctional effector cell response inhibitor (ECRI), which is a mouthful, but the concept is elegant. Exl-111 does three things at once:

1. Neutralizes free IgE, just like Xolair does.
2. Pries IgE off immune cells that are already armed, without triggering an immune reaction in the process.
3. Reduces the number of IgE receptors on those immune cells, making them harder to arm in the future.

If Xolair intercepts the letter, Exl-111 intercepts the letter, removes letters already in the mailbox, and then shrinks the mailbox. The potential result: faster symptom relief, stronger disease control, and possibly more convenient dosing.

A Phase 1 Drug for $2 Billion?

Let's address the elephant in the room. Exl-111 is still in Phase 1 testing, the earliest stage of human trials. Novartis hasn't disclosed the exact split between upfront cash and milestone payments, so we don't know how much money changes hands right now versus what's contingent on the drug actually working.

That matters. A $2 billion deal where $200 million is upfront and $1.8 billion is tied to milestones is a very different proposition than writing a $2 billion check on day one. Early pharmacokinetic data (measuring how the drug moves through the body) reportedly shows sustained exposure, which is encouraging but far from proof of efficacy.

Still, paying this much for a Phase 1 asset is a premium by any standard. Novartis is clearly betting that the IgE biology is well-validated enough (thanks to decades of Xolair data) that the real question isn't "does targeting IgE work?" but "can we do it better?"

The Bigger Chessboard

This deal doesn't exist in a vacuum. Novartis has been on an acquisition tear, and this marks its second major deal in a single week (the other being a breast cancer drug, SNV4818, from Synnovation Therapeutics, valued at up to $3 billion).

The company's immunology strategy is sprawling. Cosentyx, its blockbuster psoriasis drug, is tracking toward $8 billion in peak sales. Rhapsido (remibrutinib) just launched in the U.S. for chronic spontaneous urticaria (chronic hives). And the broader pipeline includes over 6 Phase III readouts and more than 10 Phase II readouts expected in the next five years.

Exl-111 fits neatly into this puzzle. Novartis plans to develop it across food allergy, chronic spontaneous urticaria, chronic inducible urticaria, allergic asthma, and other IgE-mediated diseases, with potential pediatric uses. If the drug works, it could become a pipeline-in-a-product, addressing multiple conditions with a single molecule.

Perhaps most telling: the field has over 12 companies working on IgE receptor-related drugs, and while some have reached late-stage development, none have yet emerged as a clear next-generation successor to Xolair across its key indications. That gives Novartis a window, albeit one it'll need several years to climb through.

The Bottom Line

Novartis is essentially paying $2 billion for an insurance policy. If Exl-111 works, it replaces Xolair revenue with something better, harder to copy, and patent-protected for years. If it doesn't, the milestone-heavy structure (presumably) limits the damage.

The transaction is expected to close in the second half of 2026, and the real story starts after that: can a tiny startup's Phase 1 molecule survive the brutal gauntlet of clinical development and emerge as a worthy successor to one of the best-selling allergy franchises in history?

Novartis is betting it can. At $2 billion, they'd better be right.